Kharbanda K, Dinda A K, Sarkar C, Karak A K, Dhir R, Mathur M, Roy S
Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi.
J Neurooncol. 1995;23(3):185-90. doi: 10.1007/BF01059949.
The labeling index (LI) of 216 cases of human brain tumors was determined by the immunohistochemical technique with monoclonal antibody to bromodeoxyuridine (BrdU). The proliferative potential of 110 cases was estimated using the intra-operative intravenous infusion of BrdU at a dose of 200 mg/sq m. In another 106 cases, the in vitro technique of incubating freshly resected tumor tissue fragments with 100 microM bromodeoxyuridine was used. The BrdU LI in these tumors was then correlated with the histological types and the data as determined by both the in vivo and in vitro BrdU incorporation were compared. The results indicate that although in vivo and in vitro techniques could possibly provide equivalent data in some histologic types, a clear statistically valid proof however is not apparent from this study.
采用抗溴脱氧尿苷（BrdU）单克隆抗体免疫组化技术测定了216例人脑肿瘤的标记指数（LI）。110例患者术中静脉输注剂量为200mg/平方米的BrdU，以评估其增殖潜能。另外106例患者采用将新鲜切除的肿瘤组织碎片与100μM溴脱氧尿苷一起孵育的体外技术。然后将这些肿瘤中的BrdU LI与组织学类型相关联，并比较体内和体外BrdU掺入所确定的数据。结果表明，虽然体内和体外技术在某些组织学类型中可能提供等效数据，但本研究中尚无明显的统计学有效证据。
